Oruka is a high-risk, well-funded clinical biotech seeking to turn validated psoriasis biologics into best-in-class, ultra-long-acting therapies with once- or twice-yearly dosing.
Overview
Oruka Therapeutics is a pre-revenue clinical-stage biotech developing long-acting biologics for chronic inflammatory skin diseases. Its lead assets, ORKA-001 and ORKA-002, are engineered to deliver high skin-clearance rates with once- or twice-yearly dosing, potentially improving compliance versus existing biologics requiring injections every 4–12 weeks. Early ORKA-001 Phase 2a data showed 63.5% PASI 100 at Week 16 after one induction dose. The thesis depends on replicating efficacy in larger trials, obtaining favorable dosing labels, and ultimately commercializing in large psoriasis, psoriatic arthritis, and hidradenitis suppurativa markets.